← Back to Home

Molgramostim Review Delayed Again: FDA to Miss November 22 Deadline, With No New Date Set

The review of an inhaled therapy for a rare lung disease will not be completed on schedule despite a three-month extension. Savara has not explained the reason for the latest delay, leaving patients and the company without a clear timeline.

By SURL BioNews

For patients with autoimmune pulmonary alveolar proteinosis, there is now another layer of uncertainty over when an inhaled therapy may be approved for use. Savara said on November 20 that the U.S. Food and Drug Administration (FDA) had notified the company that it would be unable to complete its review of the biologics license application for molgramostim inhalation solution by the November 22, 2026 target date and had not provided a new decision date.

The application had already undergone one delay. According to BioSpace, the FDA previously classified Savara’s response to an information request as a major amendment to the application, extending the review period by three months. The extended deadline will now also be missed; the company’s CEO, Matt Pauls, said it would continue working with the FDA to complete the review.

This rare lung disease involves a problem with the clearance mechanism in the alveoli. Autoantibodies in patients’ bodies block signaling by granulocyte-macrophage colony-stimulating factor (GM-CSF), preventing alveolar macrophages from adequately clearing excess surfactant. The substance that normally helps keep the alveoli open gradually accumulates, instead impairing gas exchange and causing shortness of breath, coughing, and fatigue.

Molgramostim is recombinant human GM-CSF delivered to the lungs by inhalation through a nebulizer and is being developed to improve this impaired clearance pathway. However, the rationale for its mechanism of action and the clinical study results still require a full regulatory assessment; this investigational therapy has not yet been approved by the FDA.

The key unanswered question in this announcement is why the FDA needs more time. Investing.com noted that Savara did not disclose the specific reason for the latest delay or say whether it had received new information requests or whether any particular issues had arisen with the application. Missing the target review date does not in itself mean that the FDA has rejected the application, nor is it sufficient to infer that new safety or efficacy concerns have emerged for the drug.

The uncertainty over timing has already been reflected in the market reaction. Investing.com reported that Savara’s share price fell by about 20% following the announcement; the company did not update its potential launch timeline or quantify the financial impact of the delay. For patients, the next substantive development will be a new review date, clarification of the reason for the delay, or a final regulatory decision. Until that information becomes available, how long it will take for this therapy to reach clinical use remains uncertain.

References

  1. BioSpace
  2. Savara Inc.
  3. Investing.com